Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 24146864)


P16 and p53 play distinct roles in different subtypes of breast cancer.

Shan M, Zhang X, Liu X, Qin Y, Liu T, Liu Y, Wang J, Zhong Z, Zhang Y, Geng J, Pang D.

PLoS One. 2013 Oct 11;8(10):e76408. doi: 10.1371/journal.pone.0076408. eCollection 2013.


p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.

Megha T, Ferrari F, Benvenuto A, Bellan C, Lalinga AV, Lazzi S, Bartolommei S, Cevenini G, Leoncini L, Tosi P.

J Clin Pathol. 2002 Jun;55(6):461-6.


Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.

Pape-Zambito D, Jiang Z, Wu H, Devarajan K, Slater CM, Cai KQ, Patchefsky A, Daly MB, Chen X.

PLoS One. 2014 Jun 30;9(6):e100488. doi: 10.1371/journal.pone.0100488. eCollection 2014.


Overexpressions of Cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications.

Chae SW, Sohn JH, Kim DH, Choi YJ, Park YL, Kim K, Cho YH, Pyo JS, Kim JH.

Yonsei Med J. 2011 May;52(3):445-53. doi: 10.3349/ymj.2011.52.3.445.


Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.

Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, Westra WH, Argani P.

Am J Surg Pathol. 2009 Feb;33(2):163-75. doi: 10.1097/PAS.0b013e31817f9790.


Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.

Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, Liang R, Epstein RJ, Yau T.

Med Oncol. 2012 Sep;29(3):1536-42. doi: 10.1007/s12032-011-0082-y. Epub 2011 Oct 8.


p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.

Mao XY, Fan CF, Zheng HC, Wei J, Yao F, Jin F.

J Exp Clin Cancer Res. 2010 Aug 16;29:112. doi: 10.1186/1756-9966-29-112.


Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.

Liu C, Zhang H, Shuang C, Lu Y, Jin F, Xu H, Lu P.

Med Oncol. 2010 Sep;27(3):747-52. doi: 10.1007/s12032-009-9279-8. Epub 2009 Aug 6.


Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.

Sugianto J, Sarode V, Peng Y.

Hum Pathol. 2014 Apr;45(4):802-9. doi: 10.1016/j.humpath.2013.11.013. Epub 2013 Dec 2.


In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer.

Kurbel S.

Tumour Biol. 2013 Feb;34(1):1-7. doi: 10.1007/s13277-012-0602-1. Epub 2012 Dec 4. Review.


Silencing of HSulf-2 expression in cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.

Khurana A, McKean H, Kim H, Kim SH, mcguire J, Roberts LR, Goetz MP, Shridhar V.

Breast Cancer Res. 2012 Mar 12;14(2):R43.


Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.

Vargas AC, McCart Reed AE, Waddell N, Lane A, Reid LE, Smart CE, Cocciardi S, da Silva L, Song S, Chenevix-Trench G, Simpson PT, Lakhani SR.

Breast Cancer Res Treat. 2012 Aug;135(1):153-65. doi: 10.1007/s10549-012-2123-4. Epub 2012 Jun 21.


Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.

Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC Jr, Yu Y.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3660-6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk